Viread and Congestive cardiomyopathy - a phase IV clinical study of FDA data


Congestive cardiomyopathy is found among people who take Viread, especially for people who are male, 0-1 old, have been taking the drug for 6 - 12 months.

The phase IV clinical study analyzes which people take Viread and have Congestive cardiomyopathy. It is created by eHealthMe based on reports of 46,220 people who have side effects when taking Viread from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 20, 2023

46,220 people reported to have side effects when taking Viread.
Among them, 12 people (0.03%) have Congestive cardiomyopathy.

What is Viread?

Viread has active ingredients of tenofovir disoproxil fumarate. It is often used in hepatitis b. eHealthMe is studying from 46,326 Viread users for its effectiveness, alternative drugs and more.

What is Congestive cardiomyopathy?

Congestive cardiomyopathy (weakening of heart muscle) is found to be associated with 1,515 drugs and 930 conditions by eHealthMe.

Number of Viread and Congestive cardiomyopathy reports submitted per year:

Could Viread cause Congestive cardiomyopathy?

Time on Viread when people have Congestive cardiomyopathy *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 50 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 50 %

Gender of people who have Congestive cardiomyopathy when taking Viread *:

  • female: 25 %
  • male: 75 %

Age of people who have Congestive cardiomyopathy when taking Viread *:

  • 0-1: 54.55 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 9.09 %
  • 40-49: 36.36 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

Common drugs people take besides Viread *:

  1. Lamivudine: 6 people, 50.00%
  2. Zidovudine: 6 people, 50.00%
  3. Lopinavir And Ritonavir: 6 people, 50.00%
  4. Didanosine: 6 people, 50.00%
  5. Stavudine: 6 people, 50.00%
  6. Efavirenz: 6 people, 50.00%
  7. Emtriva: 2 people, 16.67%
  8. Androgel: 2 people, 16.67%
  9. Combivir: 2 people, 16.67%
  10. Nexium: 2 people, 16.67%

Common side effects people have besides Congestive cardiomyopathy *:

  1. Arrhythmia Neonatal (irregular heartbeat-neonatal): 6 people, 50.00%
  2. Premature Baby: 6 people, 50.00%
  3. Atrioventricular Block Complete (heart block complete): 6 people, 50.00%
  4. Rashes (redness): 2 people, 16.67%
  5. Blood Testosterone Decreased: 2 people, 16.67%
  6. Nasopharyngitis (inflammation of the nasopharynx): 2 people, 16.67%
  7. Ventricular Hypertrophy (enlargement of ventricles (lower chambers) in the heart): 1 person, 8.33%
  8. Death: 1 person, 8.33%
  9. Arthropathy: 1 person, 8.33%
  10. Cardiac Disorder: 1 person, 8.33%

Common conditions people have *:

  1. Oral Candidiasis (fungal infection of mouth): 1 person, 8.33%
  2. Joint Pain: 1 person, 8.33%
  3. Hepatitis C: 1 person, 8.33%
  4. Gastritis (inflammation of stomach): 1 person, 8.33%
  5. Diarrhea: 1 person, 8.33%
  6. Blood Testosterone Decreased: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Viread and have Congestive cardiomyopathy?

Check whether Congestive cardiomyopathy is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Congestive cardiomyopathy and when was it recovered:

Expand to all the drugs that have ingredients of tenofovir disoproxil fumarate:

Alternative drugs to, pros and cons of Viread:

Common Viread side effects:

Browse all side effects of Viread:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Congestive cardiomyopathy treatments and more:

COVID vaccines that are related to Congestive cardiomyopathy:

Common drugs associated with Congestive cardiomyopathy:

All the drugs that are associated with Congestive cardiomyopathy:

Common conditions associated with Congestive cardiomyopathy:

All the conditions that are associated with Congestive cardiomyopathy:

How the study uses the data?

The study uses data from the FDA. It is based on tenofovir disoproxil fumarate (the active ingredients of Viread) and Viread (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: